MA46523A - Procédés de criblage de modulateurs d'une activité biologique de type gdf15 - Google Patents

Procédés de criblage de modulateurs d'une activité biologique de type gdf15

Info

Publication number
MA46523A
MA46523A MA046523A MA46523A MA46523A MA 46523 A MA46523 A MA 46523A MA 046523 A MA046523 A MA 046523A MA 46523 A MA46523 A MA 46523A MA 46523 A MA46523 A MA 46523A
Authority
MA
Morocco
Prior art keywords
gdf15
processes
biological activity
type biological
screening modulators
Prior art date
Application number
MA046523A
Other languages
English (en)
Inventor
Anthony Armstrong
Stephen Beck
Jose Antonio Chavez
Chen-Ni Chin
Thai Dinh
Jennifer Furman
Matt Husovsky
Xiefan Lin-Schmidt
Shannon Mullican
Shamina Rangwala
Vicki South
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA46523A publication Critical patent/MA46523A/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/495Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
MA046523A 2016-10-12 2017-10-11 Procédés de criblage de modulateurs d'une activité biologique de type gdf15 MA46523A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662407046P 2016-10-12 2016-10-12

Publications (1)

Publication Number Publication Date
MA46523A true MA46523A (fr) 2019-08-21

Family

ID=60186389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046523A MA46523A (fr) 2016-10-12 2017-10-11 Procédés de criblage de modulateurs d'une activité biologique de type gdf15

Country Status (9)

Country Link
US (1) US20190234935A1 (fr)
EP (1) EP3526346A1 (fr)
JP (1) JP2020503842A (fr)
KR (1) KR20190059312A (fr)
AU (1) AU2017342028A1 (fr)
CA (1) CA3038846A1 (fr)
IL (1) IL265808A (fr)
MA (1) MA46523A (fr)
WO (1) WO2018071493A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102370762B1 (ko) 2016-03-31 2022-03-04 엔지엠 바이오파마슈티컬스, 아이엔씨. 결합 단백질 및 이의 사용 방법
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR20210044244A (ko) 2018-08-10 2021-04-22 노파르티스 아게 Gfral 세포외 도메인 및 사용 방법
IL291985A (en) 2019-10-07 2022-06-01 Kallyope Inc gpr119 agonists
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
EP4172162A1 (fr) 2020-06-26 2023-05-03 Kallyope, Inc. Activateurs d'ampk
WO2023154953A1 (fr) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Polypeptides gdf15 pour le traitement et la prévention de maladies auto-immunes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
AU669489B2 (en) 1991-09-18 1996-06-13 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
PT665897E (pt) 1992-10-01 2003-11-28 Trustees Of Columbia U In The Bibliotecas quimicas combinatorias complexas codificadas com etiquetas
AU703472B2 (en) 1993-11-02 1999-03-25 Affymax Technologies N.V. Synthesizing and screening molecular diversity
EP0758313A4 (fr) 1994-05-06 1999-09-15 Pharmacopeia Inc Bibliotheque combinatoire de dihydrobenzopyranes
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6010861A (en) 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
PT2441466E (pt) * 2004-04-13 2014-09-09 St Vincents Hosp Sydney Agente de inibição de mic-1
CA2832581C (fr) * 2011-04-08 2022-08-23 Yumei Xiong Methode de traitement ou d'amelioration de troubles metaboliques a l'aide du facteur 15 de differenciation de croissance (gdf-15)
BR112014018575A2 (pt) * 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
CN106536553B (zh) * 2014-03-26 2021-03-12 尤利乌斯·马克西米利安维尔茨堡大学 生长和分化因子15(gdf-15)的单克隆抗体及其治疗癌性恶病质和癌症的用途
EP3157952B1 (fr) * 2014-06-20 2021-12-22 Aveo Pharmaceuticals, Inc. Traitement de l'insuffisance cardiaque congestive et d'autres dysfonctionnements cardiaques à l'aide d'un modulateur gdf15
ES2872534T3 (es) * 2014-09-25 2021-11-02 Aveo Pharmaceuticals Inc Métodos para revertir la caquexia y prolongar la supervivencia que comprenden administrar un modulador de GDF15 y un agente anticanceroso
JP2019510739A (ja) * 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Gfral受容体療法
KR102370762B1 (ko) * 2016-03-31 2022-03-04 엔지엠 바이오파마슈티컬스, 아이엔씨. 결합 단백질 및 이의 사용 방법

Also Published As

Publication number Publication date
IL265808A (en) 2019-06-30
US20190234935A1 (en) 2019-08-01
CA3038846A1 (fr) 2018-04-19
JP2020503842A (ja) 2020-02-06
EP3526346A1 (fr) 2019-08-21
WO2018071493A1 (fr) 2018-04-19
KR20190059312A (ko) 2019-05-30
AU2017342028A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
MA46523A (fr) Procédés de criblage de modulateurs d'une activité biologique de type gdf15
MA56008A (fr) Composés et compositions pour traiter des états associés à une activité de nlrp
MA46278A (fr) Molécules de liaison qui modulent une activité biologique exprimée par une cellule
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA44734A (fr) Composés et compositions destinés au traitement d'états associés à une activité de nlrp
GB202001657D0 (en) Prediction of adverse drug reactions
MA42269A (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
DK3134386T3 (da) Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
MA43756A (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
BR112016030690A2 (pt) moduladores do receptor de arila e métodos de fabricar e usar os mesmos
CL2015000717A1 (es) Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c.
GB202015400D0 (en) Adverse drug reaction analysis
MA49153A (fr) Éléments régulateurs à haute activité
DK3463351T3 (da) Behandling til parkinsons sygdom
GB201610425D0 (en) Analysis of images of biological material
MA41198A (fr) Essais d'activité enzymatique pour i2s
MA53014A (fr) Composés améliorant l'activité du protéasome
FI20155241A (fi) Menetelmä beta-spodumeenin valmistamiseksi alfa-spodumeenia sisältävästä raaka-aineesta
FR3039378B1 (fr) Ensemble de conditionnement d'un produit cosmetique
MA50838A (fr) Procédés de production de matieres végétales ensilées à l'aide de megasphaera elsdenii
IL291221A (en) Methods for the synthesis of wolbenzine
FR3046471B1 (fr) Methode de calibration d'une interface neuronale directe par regression multivoie penalisee
EP3623369C0 (fr) Nouveaux composés de morpholinyle amine pour le traitement des maladies auto-immunes